StockNews.com Begins Coverage on Eagle Pharmaceuticals (NASDAQ:EGRX)

Stock analysts at StockNews.com began coverage on shares of Eagle Pharmaceuticals (NASDAQ:EGRX) in a research report issued on Wednesday. The brokerage set a “hold” rating on the specialty pharmaceutical company’s stock.

Eagle Pharmaceuticals Stock Performance

Shares of EGRX stock opened at $0.55 on Wednesday. Eagle Pharmaceuticals has a 12-month low of $0.00 and a 12-month high of $6.81. The company has a 50 day moving average of $0.69 and a 200-day moving average of $2.78.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. DGS Capital Management LLC lifted its holdings in Eagle Pharmaceuticals by 44.9% during the third quarter. DGS Capital Management LLC now owns 71,728 shares of the specialty pharmaceutical company’s stock valued at $268,000 after purchasing an additional 22,239 shares during the last quarter. Jane Street Group LLC bought a new stake in shares of Eagle Pharmaceuticals in the third quarter valued at approximately $96,000. RBF Capital LLC lifted its stake in shares of Eagle Pharmaceuticals by 11.7% during the 3rd quarter. RBF Capital LLC now owns 143,078 shares of the specialty pharmaceutical company’s stock valued at $534,000 after buying an additional 14,991 shares in the last quarter. Jacobs Levy Equity Management Inc. bought a new position in Eagle Pharmaceuticals in the 3rd quarter worth approximately $453,000. Finally, Creative Planning purchased a new position in Eagle Pharmaceuticals in the 3rd quarter valued at approximately $59,000. Institutional investors own 85.36% of the company’s stock.

Eagle Pharmaceuticals Company Profile

Eagle Pharmaceuticals, Inc, a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin’s lymphoma.